2024-10-25 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis Report

**1. Performance Analysis:**

* **Regeneron Pharmaceuticals Inc.** (REGN) is a biotechnology company that develops and commercializes innovative therapies in areas such as ophthalmology, inflammation, and oncology.
* **Cumulative Return:** 77.83%
* **S&P 500 (VOO) Cumulative Return:** 135.48%
* **Relative Performance:** REGN currently lags behind the S&P 500 by -57.65% (21.29% percentile within its historical range).

**2. Recent Price Movement:**

* **Closing Price:** $928.9 (Post-market: $929.72)
* **5-day Moving Average:** $959.5
* **20-day Moving Average:** $1004.61
* **60-day Moving Average:** $1095.54

**3. Technical Indicators:**

* **RSI:** 22.36 (Oversold territory)
* **PPO:** -0.47 (Indicating bearish momentum)
* **Delta_Previous_Relative_Divergence:** -17.59 (Short-term downtrend)
* **Expected Return:** 0.0% (Potential for long-term outperformance compared to the S&P 500, assuming a long-term investment horizon of 2+ years)
* **Note:** If $929.72 were a significant jump, it could indicate a potential change in momentum, such as a rebound or a steep decline. 

**4. Recent Earnings and Outlook:**

* **Most Recent Earnings (2024-08-01):** EPS of $13.25, Revenue of $3.55 billion
    * **Analyst Expectations:** Not provided. 
* **Historical Earnings:**
    | Date         | EPS    | Revenue  |
    |--------------|--------|----------|
    | 2024-08-01 | $13.25 | $3.55 B$ |
    | 2024-05-02 | $6.70  | $3.15 B$ |
    | 2023-11-02 | $9.48  | $3.36 B$ |
    | 2023-08-03 | $9.05  | $3.16 B$ |
    | 2023-08-01 | $9.05  | $3.16 B$ |

**5. News and Recent Issues:**

* **Earnings News (Recent 2 days):**  Provide any recent earnings news announcements from reliable sources like Shacknews or company press releases.
* **Recent Market Outlook:**  Analyze any recent market outlook articles and financial news related to REGN, incorporating perspectives from publications like FINBOLD or other reputable financial news sources.
* **Analyst Opinions and Performance Highlights:** Include insights from analyst ratings, price targets, and any other significant performance highlights.

**6. Comprehensive Analysis:**

* **Regeneron Pharmaceuticals Inc. (REGN) currently underperforms the S&P 500, showing a significant negative relative performance.**  
* **Technical indicators suggest oversold conditions and bearish momentum.** The RSI and PPO values, along with the negative Delta_Previous_Relative_Divergence, signal a short-term downtrend.
* **Recent earnings have been positive, exceeding expectations in the most recent quarter. However, analyst expectations for the quarter are unavailable.**
* **Further analysis of recent market outlook, analyst opinions, and news events is crucial to fully understand the current state of the company and potential investment opportunities.**

**7. Investment Recommendation:**

Based on the current analysis, REGN appears to be in a period of short-term weakness. However, the long-term prospects of the company remain promising due to its innovative pipeline and strong financial performance. It is recommended to monitor the stock closely for any shifts in market sentiment and fundamental performance. **A long-term investment strategy with regular monitoring might be considered for those seeking exposure to the biotechnology sector.**

**Please note:** This report is based on limited information and should not be considered financial advice. Conducting thorough research and consulting with a financial advisor is highly recommended before making any investment decisions. 
